Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

The push to develop the first oral GLP-1 receptor drug for obesity is heating up, as four phase 3 drugs race to become the first approved oral treatment for obesity, Global Data reported Dec. 2. Here ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

The connection between weight loss medications and addiction reduction represents a potentially transformative discovery in ...

With the growing demand for GLP-1 drugs for weight loss, a high percentage of medication users are experiencing temporary and long-term side effects from these rapid weight loss methods. Kelker Pharma ...

Inc., a raw material distributor in the dietary supplement industry and exclusive U.S. distribution partner to CarnoSyn® Brands and ...

Health care stocks have underperformed in recent months on uncertainty surrounding the incoming Donald Trump administration, but they can often be a solid defensive play in an uncertain economy.

Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...

Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, ...